To discover and inhibit metabolic dependencies in neoplastic and microenvironment cells in pancreatic cancer.
Tumor metabolism in pancreatic cancer is highly unusual, as the cancer cells scavenge nutrients from the stroma and rely symbiotically on the stroma. The intra-tumoral metabolism creates therapeutic challenges, including promoting cachexia and attenuating the immune response, but also creates potential for novel drug targets and therapeutic approaches in pancreatic cancer.
Develop a focused research strategy whereby the Foundation will work with leading researchers and support their dedicated efforts to discover aberrant metabolic pathways in pancreatic cancer and determine their relationship to cachexia, local immune regulation, and as potential therapeutic targets.
Targeted Research Areas include, but are not restricted to:
- Identify the metabolic aberrations of pancreatic cancer cells and stroll cells using model systems.
- Determine how the dysregulated metabolism causes cachexia in pancreatic cancer.
- Evaluate which of these aberrant metabolic pathways represent feasible drug targets.
- Conduct preclinical proof-of-concept studies that may serve as a step towards clinical translation.
Letter of Intent Due: June 30, 2020
LOI Notification: July 31, 2020
Full Proposal Due: October 1, 2020
Earliest Anticipated Start Date: January 1, 2021
Questions regarding this Request for Proposals should be directed to:
Andrew Rakeman, Ph.D.